Granted US patent on specific sequence-defined bispecific antibodies that bivalently bind Aβ plaques and monovalently bind TfR1; covers the structural format used in trontinemab for enhanced CNS delivery.

Evidence span

Granted US patent on specific sequence-defined bispecific antibodies that bivalently bind Aβ plaques and monovalently bind TfR1; covers the structural format used in trontinemab for enhanced CNS delivery.

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Specific CDR/VH/VL sequences for bispecific anti-Aβ/anti-TfR1 antibodies (variants 0012, 0015, 0020, 0024); 2+1 format with bivalent Aβ and monovalent TfR1 arms; methods of use for Alzheimer's disease BBB-crossing drug delivery.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required